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ABSTRACT 
A 35 year-old para 1+0 underwent MRgFUS per study protocol for multiple uterine fibroids, the largest of which 
measured  5  cm.  She  conceived  10  months  following  the  procedure.  The  patient  was  induced  at  41+6  weeks  and 
underwent a normal vaginal delivery. © 2010 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Magnetic  Resonance-guided  Focused  Ultrasound 
Surgery  (MRgFUS)  was  developed  as  a  non-invasive 
alternative  to  conventional  surgical  techniques.  It 
combines  the  use  of  high-powered  ultrasound  energy 
with Magnetic Resonance (MR) technology for accurate 
visualisation,  control  and  feedback,  allowing  for  safe 
thermo-ablation  of  tumours.  The  U.S.  Food  and  Drug 
Administration (FDA) approved the technology in 2004. 
Data supporting the safety and efficacy of MRgFUS as 
an alternative treatment option for symptomatic uterine 
fibroids have been published previously [1, 2].  
MRgFUS  offers  several  advantages  for  treating 
uterine fibroids, in that it is a completely non-invasive, 
outpatient procedure that requires minimal sedation and 
allows  for  a  speedy  recovery.  Patients  undergoing 
MRgFUS  typically  return  to  work  within  24  hours, 
compared  with  ten  days  after  Uterine  Artery 
Embolisation (UAE) and 6 weeks after myomectomy or 
hysterectomy. The initial FDA recommendation was that 
only women who had completed their families should be 
treated with MRgFUS. However, with the advantage of 
consistently  good  safety  and  efficacy  results  being 
reported, multi-centre fertility studies were commenced 
and  are  on-going.  These  studies  are  recruiting  women 
with symptomatic uterine fibroids, who wish to become 
pregnant. The non-invasive nature of ExAblate, whereby 
only the uterine fibroids undergo thermal ablation with 
no damage to healthy surrounding tissue, suggests that 
MRgFUS  should  be  a  safe  approach  for  women  who 
want to preserve their fertility. 
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CASE  
A  39  year-old  para  1+0  presented  to  the  fibroid 
clinic at the authors’ hospital with a known diagnosis of 
fibroids made 3 years ago. The patient’s first pregnancy 
resulted in a premature delivery at 28 weeks (attributed 
to fibroids) of a 1.17kg female infant. She presented to 
the unit with a history of fibroid-related menorraghia and 
urinary  pressure  symptoms  including  frequency  and 
nocturia.  Symptoms  were  assessed  using  the  Uterine 
fibroid-specific quality of life Questionnaire (UFS-QOL) 
[3]. The patient’s baseline score was 65. The severity of 
symptoms is directly related to the greatness of the score 
with a maximum score being 100.  
In July 2006, a radiological MRI assessment deemed 
the patient to be suitable for treatment with MRgFUS. 
She was enrolled in an ongoing clinical trial of MRgFUS 
for treatment of symptomatic fibroids, where the subjects 
consisted of  women  wishing to preserve their fertility. 
The  patient  gave  informed  consent  and  fulfilled  all 
eligibility criteria for the study. 
The patient’s screening MRI (see fig.1) revealed an 
enlarged fibroid uterus with an inferio-superior diameter 
of  13.5  cm.  Five  fibroids  were  identified,  the  largest 
being a fundal posterior intra-mural fibroid of 5 cm, as 
well as three other anterior intramural fibroids, and a low 
anterior  wall  fibroid  of  4.5  cm  which  distorted  the 
endometrial  cavity  posteriorly.  All  fibroids  showed  a 
hypo-intense signal as compared to myometrial tissue on 
T2-weighted imaging.  
The patient had a pre-treatment course of 3 GnRH 
analogue s/c injections, of which the first was given on 
the  first  day  of  the  cycle  and  subsequent  injections 
28 days after the previous. She then underwent MRgFUS 
treatment  in  October  2006.  Immediate  post-treatment 
contrast-enhanced images revealed excellent results with 
approximately  90%  non-perfusion  of  total  fibroid 
volume achieved. 
The  treatment  did  not  produce  any  complications 
and  the  patient  was  discharged  on  the  same  day.  By 
6 months  post-procedure,  the  patient  had  experienced 
almost  complete  resolution  of  her  pre-treatment 
symptoms, with her UFS-QOL score now 24. The patient 
conceived  4  months  later,  with  no  antenatal  problems 
noted at booking. All booking observations were normal. 
An anomaly scan performed at 20 weeks gestation again 
revealed no abnormalities. Serial sonography at 28, 32, 
36 and 40 weeks demonstrated appropriate foetal growth 
with  cephalic  presentation  and  an  anterior  placenta, 
 
Figure 1  T2 weighted sagittal image prior to treatment. Maximum uterine dimension measuring 13.9cm, uterine 
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which was not low-lying. There were no myomata viable 
on the 40-week scan. 
At  41  +6  weeks  the  patient  was  admitted  for 
induction of labour as she was past her due date. Labour 
was  augmented  by  artificial  rupture  of  the  membranes 
and  lasted  for  5  hours  8  minutes.  Foetal  monitoring 
throughout was reassuring, and an uncomplicated vaginal 
delivery of a healthy female infant with a birth weight of 
3580gms was achieved. Apgar scores were 8 at 1 minute, 
9 at 5 minutes and 9 at 10 minutes. In the institution at 
which the patient delivered, cord gases are not routinely 
done  for  non-distressed  infants.  No  paediatrician  was 
required at delivery. 
At 6 months post-delivery, the patient continued to 
maintain symptomatic improvement, with a QOL of 22. 
Contrast-enhanced MRI shows persistent non-perfusion 
of all fibroids; in addition, there has been a shrinkage in 
the overall uterine volume of 2.5 cm. 
DISCUSSION 
The relationship between leiomyomas and infertility 
remains a subject for debate. The incidence of myomas 
in  infertile  women  without  any  obvious  cause  of 
infertility is estimated to be between 1% and 2.4% [4]. 
However, there are no studies that compare pregnancy 
rates in women with and without fibroids, and the causal 
relationship  seems  to  have  been  assumed  from  case 
studies of women who have conceived after their fibroids 
were removed [5]. 
A  shift  in  cultural  trends  of  women  delaying 
pregnancy has resulted in many women presenting with 
symptomatic fibroids at a stage when preservation of the 
uterus is a priority. The National Office of Statistics in 
the  United  Kingdom  reports  a  74%  increase  in  the 
number of conceptions in the 40-44 age group in 2004, 
when compared to that of 1988 [?]. This has resulted in a 
dilemma  for  the  gynaecologist  who  is  faced  with 
providing  an  effective  solution  to  his  patient’s  fibroid 
symptoms, while ensuring no detrimental effect on her 
fertility.  The  current  standard  of  practice  remains 
surgical in the many forms of myomectomy (laparotomy, 
laparoscopy, hysteroscopy). 
Despite myomectomy being the gold standard, few 
studies agree on the actual increase in pregnancy rates 
following surgery, this being described as anything from 
44%-81%;  however,  all  report  a  fall  in  the  rate  of 
pregnancy loss [6-9]. 
Unfortunately fertility enhancement is not the only 
factor to be considered when recommending treatment; 
complications related to fibroid removal also have to be 
 
Figure 2  Contrast enhanced image showing non-perfusion of all fibroids, and overall shrinkage. Uterine volume 
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taken  into  account.  During  myomectomy,  part  of  the 
uterine wall is severed in order to enucleate the fibroid. 
This damage to the wall is independent of the surgical 
technique used. Surgical sutures are placed in order to 
control  bleeding  and  close  the  severed  uterine  wall, 
which  results  in  a  fibrotic  scar.  In  addition  to  the 
resulting  relative  weakness  of  the  uterine  wall  post-
surgery – which may result in the low but major risk of 
uterine rupture during pregnancy/labour – adhesions can 
also form within the abdomen, resulting in mechanical 
infertility.  
A  further  point  to  be  considered  is  the  risk  of 
surgery-associated  complications.  Even  if  uncommon, 
intra-operative  complications,  such  as  bladder,  bowel, 
ureteral  injury,  severe  bleeding  and  unintended 
conversion  to  hysterectomy,  have  been  reported. 
Moreover, post-operative complications, such as fistula 
or thrombosis and embolism, may also occur [10]. The 
minimally  invasive  treatment  option  of  UAE  has 
increased  in  popularity  and  reported  pregnancies 
following  treatment  are  plentiful.  Although  most 
pregnancies  following  UAE  have  good  outcomes,  the 
risk  of  pre-term  delivery,  spontaneous  abortion, 
abnormal placentation and post-partum haemorrhage, are 
increased  following  uterine  artery  embolisation 
compared  to  myomectomy.  This  may  be  due  to  the 
resultant ischaemia, which not only occurs in the fibroid, 
but  the  entire  uterus.  This  ischaemia  may  result  in 
chronic weakness of the pregnant uterus. Uterine rupture 
has been reported with both myomectomy and UAE. 
Although both myomectomy and UAE are seen as 
effective  and  safe  treatment  options  for  fibroids,  the 
increase  in  pregnancy  complications  seen  with  UAE 
means  that  patients  desiring  future  fertility  should  be 
recommended myomectomy  as the treatment of choice 
over UAE. 
With MRgFUS, heat ablation is limited to the core 
of the fibroid and no damage to the surrounding uterine 
wall  occurs.  Real-time  monitoring  of  the  volume  of 
ablation enables limitation of the thermal damage to a 
distinct  targeted  region  of  the  fibroid  as  shown  in 
pathology  specimens  [11]  and  MR-contrast  imaging. 
Accordingly, there arises the hypothesis that MRgFUS 
may enable non-invasive treatment of uterine fibroids in 
women desiring pregnancy, without compromise to the 
integrity of the uterus or increase in pregnancy-related 
risks. 
 This  out-patient  procedure  with  minimal  sedation 
requirements and a speedy recovery time, allows patients 
to return to work within 24 hours, compared to 10 days 
after UAE and 6 weeks with myomectomy. Over 4000 
women  with  symptomatic  uterine  fibroids  have  been 
treated worldwide. Published studies have shown that up 
to  84.6%  of  women  treated  experienced  significant 
symptomatic improvement at 24 months post-treatment 
follow  up  [12].  However,  initial  FDA  guidelines  still 
recommend that only women who have completed their 
families  undergo  this  treatment,  despite  there  having 
been  three  published  studies  of  achieved  pregnancies 
following MRgFUS treatment [13-16]. 
This  paper  describes  the  first  pregnancy  and 
successful  delivery  in  a  woman  who  was  part  of  a 
fertility trial and specifically treated with MRgFUS for 
symptomatic  fibroids  that  had  caused  a  previous 
premature delivery at 28 weeks. 
Fertility data continues to accumulate and the results 
are encouraging. MRgFUS appears to be a safe fertility-
preserving treatment option for fibroids.  
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